This procedural win removes a near-term distraction for Regeneron, keeping the patent case on its current track. Traders should watch for upcoming summary judgment or claim construction rulings, which could materially shift the risk profile for Eylea biosimilar competition from Amgen's Pavblu.
Drug in focus
REGN drug pipeline →EYLEA HD
● Neutral Named in this court ruling- Impact
- Phase
- Approved
- Time to market
- Already approved and on the market (since August 2023)
- Next catalyst
- None dated
What to watchEYLEA HD is a mature commercial asset, watch quarterly sales trends as a pulse check on how well Regeneron is defending share against Roche's Vabysmo and upcoming biosimilars (Samsung Bioepis Opuviz eligible Jan 2027). The real binary catalyst for REGN in the next 12 months is garetosmab's PDUFA in August 2026 for FOP. EYLEA HD's contribution is a gradual commercial story, not a binary event.
- ● Otarmeni 3/10 Approved (accelerated approval) · BLA filing 2026
- ▲ Cemdisiran 6/10 Filed/PDUFA (Phase 3 NIMBLE complete; NDA under FDA Priority Review)
- ▲ Dupixent 4/10 Approved (marketed since 2017; additional Phase 3 trials ongoing for label expansion)
- ● Evkeeza 4/10 Approved
- ● Libtayo 4/10 Approved
- 11 more · All REGN drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 12 $797.99entry
- T+1 · 3mo ago +1.00%α +0.30% · $805.97
- T+5 · 3mo ago +5.37%α +5.81% · $840.84
- T+20 · 2mo ago −0.59%α +1.30% · $793.26
- T+60 · 12d ago +13.15%α +18.26% · $902.90
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
The court denied Amgen's motion to remand the aflibercept (Eylea) patent litigation back to the Central District of California, keeping the MDL in the Northern District of West Virginia. This is a procedural win for Regeneron, preserving the court's familiarity with the patents and avoiding a restart in a new forum. The ruling maintains the current litigation trajectory, which has already seen all other defendants settle, leaving Amgen as the sole remaining defendant in the MDL.
Court Ruling Details
Key Facts
- Amgen's motion for suggestion of remand was DENIED.
- The MDL (1:24-MD-3103) concerns Regeneron's biologic Eylea (aflibercept) patents.
- All other defendants in the MDL have settled, leaving only Amgen.
- The court cited its familiarity with the case and the inefficiency of remand as reasons for denial.
- The ruling was issued by Chief Judge Thomas S. Kleeh on August 11, 2026.
Financial Impact
No monetary damages awarded or quantified in this procedural ruling. The ruling preserves the current litigation forum, avoiding potential delays and costs of a transfer.
Risk Factors
- The underlying patent infringement case against Amgen remains unresolved and could result in adverse findings.
- Amgen may appeal this procedural ruling, though the standard for interlocutory appeal is high.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-2ac00a9fd8-REGN |
Track record
53 reports on REGN
11 of 16 bullish or bearish reports moved the stock their way by T+20. Best: +31.76% at T+20 after the Oct 6, 2026 report. 16 of 20 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 2/10 Entry $951.23 Now $952.40 +0.12% settles Dec 16
- Nov 16, 2026today 144 Neutral 2/10 Entry $948.00 Now $952.40 +0.46% settles Dec 16
- Nov 12, 20264d ago Press Release Bullish 5/10 Entry $955.47 Now $952.40 −0.32% settles Dec 14
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
- Nov 5, 202611d ago Insider Cluster Neutral 3/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
- Nov 4, 202612d ago 144 Neutral 1/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more, parsed and scored by AI.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers